PUBLIKATIONSLISTE (Stand 26.04.2009)
ORIGINALARBEITEN DER LETZTEN FÜNF JAHRE
2009
Evaluation of high-resolution melting analysis as a diagnostic
tool to detect the BRAF V600E mutation in colorectal tumors.
Pichler M, Balic M, Stadelmeyer E, Ausch C, Wild M, Guelly C,
Bauernhofer T, Samonigg H, Hoefler G, Dandachi N. J Mol Diagn. 2009;
11(2):140-7.
Endocrine therapy plus zoledronic acid in premenopausal breast
cancer.
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G,
Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M,
Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny
W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R;
ABCSG-12 Trial Investigators, Marth C. N Engl J Med. 2009;
360(7):679-91.
2008
Optimization of diagnostic ELISA-based tests for the detection of
auto-antibodies against tumor antigens in human serum.
Stefatic, D; Riederer, M; Balic, M; Dandachi, N; Stanzer, S; Janesch,
B; Resel, M; Ler, D; Samonigg, H; Bauernhofer, T. Bosn J Basic Med
Sci. 2008; 8(3): 245-250.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal
women with early-stage breast cancer: 5-year follow-up of the
ABCSG-12 bone-mineral density substudy.
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann
H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P,
Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E,
Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and
Colorectal Cancer Study Group (ABCSG). Lancet Oncol. 2008;
9(9):840-9.
Anemia is a significant prognostic factor in local relapse-free
survival of premenopausal primary breast cancer patients receiving
adjuvant cyclophosphamide/methotrexate/5-fluorouracil
chemotherapy.
Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert
M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch
R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter
R, Gnant M; Austrian Breast and Colorectal Cancer Study Group. Clin
Cancer Res. 2008; 14(7):2082-7.
Cyclin D1 expression in breast cancer patients receiving adjuvant
tamoxifen-based therapy.
Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger
W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M,
Gnant MF, Filipits M; Austrian Breast and Colorectal Cancer Study
Group. Clin Cancer Res. 2008;14(6):1767-74.
Expansion and resistance to apoptosis of CD4+CD25+high regulatory
T cells in patients with metastatic epithelial cancer.
Stanzer S., Dandachi N., Balic M., Resel M., Samonigg H.,
Bauernhofer T. J Clin Immunol. 2008; 28(2):107-14. Epub 2007 Oct 16.
2007
The predictive value of EGFR and HER-2/neu in tumor tissue and
serum for response to anthracycline based neoadjuvant chemotherapy
of breast cancer.
Schippinger W., Dandachi N., Regitnig P., Hofmann G., Balic M.,
Neumann R., Samonigg H., Bauernhofer T. J Am Clin Pathol 2007;
128(4):630-7.
Immunomagnetic CD45 Depletion does not improve CK20 RT-PCR in
Colorectal Cancer.
Ausch C., Dandachi N., Buxhofer-Ausch V., Balic M., Bauernhofer T.,
Garschall K., Huber K., Hinterberger W., Braun S., Schiessel R. Clin
Chem Lab Med. 2007; 45(3):351-6.
2006
Immunohistochemical and mutational analysis of PDGF and PDGFR in
desmoids tumours: is there a role for tyrosine kinase inhibitors in
c-kit-negative desmoid tumours?
Liegl B, Leithner A, Bauernhofer T, Windhager R, Guelly C, Regauer
S, Beham A. Histopathology. 2006 Dec;49(6):576-81.
Evaluation of the prognostic significance of androgen receptor
expression in metastatic breast cancer.
Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T,
Samonigg H, Moinfar F. Virchows Arch. 2006; 449(1):24-30.
Plasmapheresis reverses all side-effects of a cisplatin
overdose--a case report and treatment recommendation.
Hofmann G, Bauernhofer T, Krippl P, Lang-Loidolt D, Horn S, Goessler
W, Schippinger W, Ploner F, Stoeger H, Samonigg H. BMC Cancer. 2006;
6:1.
Recurrent endometrial stromal sarcoma after treatment with
high-dose chemotherapy and autologous stem-cell support: A case
report.
Klaritsch P, Reich O, Regauer S, Bauernhofer T. Eur J Gynaecol Oncol.
2006;27(3):297-8.
Frequency of Febrile Neutropenia in Breast Cancer Patients
Receiving Epirubicin and Docetaxel/Paclitaxel with
Colony-Stimulating Growth Factors: A Comparison of Filgrastim or
Lenograstim with Pegfilgrastim.
Schippinger W, Holub R, Dandachi N, Bauernhofer T, Samonigg H.
Oncology (Basel). 2006; 70(4):290-293.
2005
Adrenocortical carcinomas and adrenal pheochromocytomas: mass and
enhancement loss evaluation at delayed contrast-enhanced CT.
Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T,
Trummer H, Schoellnast H, Preidler KW, Samonigg H. Radiology. 2005
Feb; 234(2):479-85.
Comparison of two methods for enumerating circulating tumor cells
in carcinoma patients.
M. Balic, N. Dandachi, G. Hofmann, H. Samonigg, H. Loibner, A.
Obwaller, A. van der Kooi, A. Tibbe, GV. Doyle, LWMM Terstappen, T.
Bauernhofer. Cytometry Part B 2005; 68B:25-30.
Critical evaluation of CK 20 real time PCR for the detection of
micrometastases in the peripheral blood of patients with colorectal
cancer.
N. Dandachi N, Balic M, Stanzer S, Halm M, Resel M, Hinterleitner
TA, Samonigg H, Bauernhofer T. J Mol Diagnostics 2005; 7:631-637.
Association of disease progression and poor overall survival with
detection of circulating tumor cells in peripheral blood of patients
with metastatic breast cancer.
Bauernhofer T, Zenahlik S, Hofmann G, Balic M, Resel M, Pirchmoser
R, Regitnig P, Ambros P, Dandachi N, Samonigg H. Oncol Rep. 2005
Feb;13(2):179-84.
2004
The course of serum HER-2/neu levels as an independent prognostic
factor for survival in metastatic breast cancer.
Schippinger W, Regitnig P, Bauernhofer T, Ploner F, Hofmann G,
Krippl P, Wehrschutz M, Lax S, Carney W, Neumann R, Wernecke KD,
Samonigg H. Oncol Rep. 2004 Jun;11(6):1331-6.
2003
Acute pseudo-obstruction of the small intestine following
high-dose chemotherapy and stem cell transplantation T.
Bauernhofer, M. Eibl, F. Ploner, I. Kuss, J. Pfeifer, H. Sill, H.
Samonigg. Onkologie, 2003; 26:344-346.
Randomised trial: One cycle of anthracycline-containing adjuvant
chemotherapy compared with six cycles of CMF treatment in
node-positive, hormone receptor-negative breast cancer patients.
Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M,
Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler
G, Steger G, Seifert M, Kubista E, Samonigg H; Austrian Breast And
Colorectal Cancer Study Group. Onkologie. 2003 Apr;26(2):115-9.
Preferential apoptosis of CD56+dim natural killer cell subset in
patients with cancer. T. Bauernhofer, I. Kuss, B. Henderson, AS.
Baum, TL. Whiteside. European Journal of Immunology 2003;
33:119-124.
The role of CD25 and prolactin receptor expression in the
protection of circulating T lymphocytes from apoptosis in patients
with breast cancer. T. Bauernhofer, I. Kuss, U. Friebe-Hoffmann,
G. Dworacki, A. S. Baum, B. Vonderhaar, TL. Whiteside. British
Journal of Cancer 2003; 88(8): 1301-1309.
|